Cessatech A/S

Equities

CESSA

DK0061411964

End-of-day quote NORDIC GROWTH MARKET Other stock markets 23:00:00 02/06/2024 BST			5-day change	1st Jan Change
6.24 ^DKK	+4.35%		+1.63%	-14.05%

05-27	Cessatech A/S Reports First Patient Dosed in Final Safety Study 0202 of Lead Product Candidate CT001	CI
05-15	Cessatech A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Cessatech A/S Appoints Adam Steenberg as New Chairman of the Board as of July 1, 2021

June 29, 2021 at 07:07 am

On 29 June 2021 Cessatech A/S announced that the Board of Directors has appointed Adam Steenberg as the new Chairman of the Board as of July 1, 2021. Adam Steensberg is Chief Medical Officer and Head of R&D at Zealand Pharma and has been on the Board of Cessatech since August 2020. His experience in bringing medicines through late-stage development to commercialization will be important as Cessatech moves into the next development phase with the planned initiation of the first pivotal trial for CT001 in the second half of 2021.

Latest news about Cessatech A/S

Cessatech A/S Reports First Patient Dosed in Final Safety Study 0202 of Lead Product Candidate CT001	05-27	CI
Cessatech A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
Cessatech A/S Reports Earnings Results for the Full Year Ended December 31, 2023	02-29	CI
Cessatech A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-16	CI
Cessatech A/S Announces the Paediatric Committee Agrees to Reduce the Number of Required Children in the Final Clinical Study with CT001 from 300 to 150 Children	25/10/23	CI
Cessatech Announces Last Participant Dosed in Pivotal Trial 0205 with Lead Candidate CT001	21/09/23	CI
Cessatech Wins EU Nod for Clinical Studies of Nasal Sedation Spray in Children; Shares Soar 21%	12/09/23	MT
Cessatech A/S Announces EMA's Paediatric Committee Agrees to Paediatric Investigational Plan for CT002 for Procedural Sedation	12/09/23	CI
Cessatech A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	24/08/23	CI
Cessatech A/S Secures DKK 5 Million Loan Facility Agreement to Support the US Launch of its Lead Program CT001	17/08/23	CI
Cessatech A/S and Ventis Pharma Announce US Partnership for CT001	27/06/23	CI
Cessatech A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	29/04/23	CI
Cessatech A/S Appoints Martin Olin as the Chairman of the Board	23/03/23	CI
Cessatech A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	01/03/23	CI
Cessatech A/S Reports Earnings Results for the Full Year Ended December 31, 2022	28/02/23	CI
Cessatech A/S Auditor Raises 'Going Concern' Doubt	27/02/23	CI
Cessatech A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	18/11/22	CI
Cessatech to Raise $2 Million in Rights Offer	14/11/22	MT
Cessatech Reports Successful Outcome of Pharmacokinetic Trial in Children of Lead Candidate	23/09/22	CI
Cessatech A/S Reports First Patient Dosed in Pivotal Trial of Lead Product Candidate	05/09/22	CI
Cessatech A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	19/08/22	CI
Cessatech A/S Announces Pivotal Trial 0205 Has Obtained Regulatory Approval	30/06/22	CI
Cessatech Reports Last Patient Dosed in Pharmacokinetic Trial in Children of Lead Candidate	16/05/22	CI
Cessatech A/S Reports Earnings Results for the First Quarter Ended March 31, 2022	19/04/22	CI
Cessatech A/S Announces Board Changes	17/03/22	CI

Chart Cessatech A/S

Duration

Period

More charts

Company Profile

Sector

More about the company

Income Statement Evolution

More financial data